Hello, everyone, and how are you today? We are doing just fine, thank you, now that a warm and shiny sun has risen over the otherwise chilly Pharmalot campus. Moreover, our short people have scurried off to their destinations, our official mascot is happily snoozing on his couch, and our coffee kettle is heating up another cup of stimulation — almond toffee is our choice today. So this brings us to the task at hand, which is to forage for interesting items. Speaking of which, here are some tidbits. Have a lovely day and best of luck. …

Purdue Pharma agreed to settle the state of Oklahoma’s claims that its illegal marketing of the Oxycontin painkiller caused financial devastation to local communities, the first accord in a recent wave of lawsuits stemming from the U.S. opioid crisis, according to Bloomberg News. The settlement comes two months before the scheduled start of a trial against Purdue, Johnson & Johnson (JNJ), and Teva Pharmaceutical (TEVA). Oklahoma claims the three opioid makers understated the risks of prescription painkillers and overstated their benefits, fueling an epidemic.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy